Skip to main content

Advertisement

SpringerLink
Log in

Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

  • Editorial Commentary
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The gold standard for inducing remission in systemic necrotizing vasculitis (SNV) and severe lupus nephritis is (and remains) the combination of cyclophosphamide and glucocorticoids. Long-term treatment with cyclophosphamide is limited because of toxicity. Recent prospective studies in antineutrophil cytoplasmic antibody (ANCA)-associated SNV revealed that after achievement of clinical remission (usually within 3–4 months after starting cyclophosphamide) cyclophosphamide can be replaced by azathioprine with no increase in relapse rates if treatment is continued for at least 1 year. Methotrexate is inferior to cyclophosphamide because of increased relapse rates—particularly in those with renal involvement—during follow-up. An ongoing study comparing mycophenolate mofetil (MMF) with azathioprine will clarify whether MMF is as successful as azathioprine or even better. The concomitant use of tumor necrosis factor (TNF)-α blockers increases the efficacy of immunosuppression. TNF-α blockers may be added if SNV is refractory to standard immunosuppressive therapy. However, with this addition to therapy, systemic infections are more frequent. In patients with severe lupus nephritis (WHO IV) the efficacy of combined i.v. therapy with cyclophosphamide and glucocorticoids was shown by NIH trials. This NIH regimen competes with the EURO-Lupus nephritis schedule with a lower dose of i.v. cyclophosphamide followed by maintenance therapy with azathioprine. Long-term follow-up is, however, still lacking in the EURO-Lupus trial. Ongoing prospective studies will reveal whether cyclophosphamide may be substituted by MMF from the very beginning or whether MMF is superior to azathioprine during maintenance therapy of lupus nephritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fauci AS, Wolff SM (1973) Wegener’s granulomatosis, studies in 18 patients and a review of the literature. Medicine (Baltimore) 52:535–561

    Google Scholar 

  2. Arnold H, Borseaux F (1958) Synthese und Abbau cytostatisch wirksamer cyclischer N-Phosphoamidester des Bis-(beta-chloräthyl)-amins. Angew Chemie 70:539–544

    CAS  Google Scholar 

  3. Grochow LB, Colvin M (1979) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 4:380–394

    CAS  PubMed  Google Scholar 

  4. Gayraud M, Guillevin L, Le Toumelin P, Cohen P, Lhote F, Cassasus P, Jarrousse B, French Vasculitis Study Group (2001) Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675

    Article  CAS  PubMed  Google Scholar 

  5. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, Leavitt RY (1995) Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med 151:795–799

    CAS  PubMed  Google Scholar 

  6. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Hoffman GS, Fauci AS, Sneller S (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477–484

    CAS  PubMed  Google Scholar 

  7. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM (2002) Fertility after treatment for Hodgkin’s disease. Ann Oncol 13 [Suppl 1]:138–147

    Google Scholar 

  8. Hagen EC, Andrassy K, Csernok E, Daha MR, Gaskin G, Gross WL, Hansen B, Heigl Z, Hermans J, Jayne D, Kallenberg CG, Lesavre P, Lockwood CM, Ludemann J, Mascart-Lemone F, Mirapeix E, Pusey CD, Rasmussen N, Sinico RA, Tzioufas A, Wieslander J, Wiik A, Van der Woude FJ (1996) Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA): a report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 196:1–15

    Article  CAS  PubMed  Google Scholar 

  9. Hauer HA, Bajema IM, Houwelingen HC van, Ferrario F, Noel LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC; European Vasculitis Study Group (EUVAS) (2002) Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61:80–89

    Article  PubMed  Google Scholar 

  10. Hoffmann GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis, an analysis of 158 patients. Ann Intern Med 116:488–498

    PubMed  Google Scholar 

  11. De Groot K, Adu D, Savage C (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018–2027

    Article  PubMed  Google Scholar 

  12. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, Pertuiset E, Gilson B, Hamidou M, Lanoux P, Bruet A, Ruivard M, Vanhille P, Cordier JF (2003) Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49:93–100

    Article  CAS  PubMed  Google Scholar 

  13. Jayne DR, Rasmussen N (1997) Treatment of anti-neutrophil cytoplasm autoantibody associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 72:737–747

    CAS  PubMed  Google Scholar 

  14. Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E (1991) Wegener granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 35:139–147

    CAS  PubMed  Google Scholar 

  15. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, Groot K de, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44

    Article  CAS  PubMed  Google Scholar 

  16. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, Godeau B, Ruel M, Vidal E, Piontud M, Ducroix JP, Lassoued S, Christoforov B, Babinet P (1997) Treatment of good prognosis polyarteritis nodosa and Churg-Strauss-syndrome: comparison of steroids and two cyclophosphamide regimens in 25 patients. Br J Rheumatol 36:1290–1297

    Article  CAS  PubMed  Google Scholar 

  17. Reinhold-Keller E, Fink C, Herlyn K, Gross WL, Groot K de (2002) High rate of renal relapse in 71 patients with Wegener granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 47:326–332

    Article  CAS  PubMed  Google Scholar 

  18. Stegeman CA, Cohen Tervaert JW, Jong PE de, Kallenberg CG (1996) Trimethoprim-sulfamethaxozole (co-trimoxazole) for the prevention of relapse of Wegener granulomatosis. N Engl J Med 335:16–20

    Article  CAS  PubMed  Google Scholar 

  19. Gaskin G, Jayne DRW (2002) Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J Am Soc Nephrol 13:F-FC-010

    Google Scholar 

  20. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, Woude FJ van der; for the European Vasculitis Study Group (2004) Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65:1440–1448

    Article  CAS  PubMed  Google Scholar 

  21. Cameron JS (1999) Lupus nephritis. J Am Soc Nephrol 10:413–424

    CAS  PubMed  Google Scholar 

  22. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 125:549–557

    CAS  PubMed  Google Scholar 

  23. Boumpas DT, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745

    Article  CAS  PubMed  Google Scholar 

  24. Mok CC, Ho CTK, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC (2001) Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38:256–264

    CAS  PubMed  Google Scholar 

  25. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2002) Immunosuppressive therapy in lupus nephritis. The Euro-Lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131

    Article  CAS  PubMed  Google Scholar 

  26. Chan TM, Li FK, Tang CS, Wong RWS, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162

    Article  CAS  PubMed  Google Scholar 

  27. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980

    Article  CAS  PubMed  Google Scholar 

  28. Lamprecht P, Voswinkel J, Lielienthal T, Nolle B, Heller M, Gross WL, Gause A (2002) Effectiveness of TNF-α blockade with infliximab in refractory Wegener granulomatosis. Rheumatology 41:1303–1307

    Article  CAS  PubMed  Google Scholar 

  29. Stone JH (2003) Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis. Kidney Blood Press Res 26:240–248

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University Hospital Heidelberg, Bergheimerstrasse 56a, 69115 Heidelberg, Germany

    J. H. M. Beimler & K. Andrassy

Authors
  1. J. H. M. Beimler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Andrassy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. H. M. Beimler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beimler, J.H.M., Andrassy, K. Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?. Pediatr Nephrol 19, 949–955 (2004). https://doi.org/10.1007/s00467-004-1553-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-004-1553-6

Keywords

Search

Navigation